SCHEMBL18878950

SCHEMBL18878950

CNc1noc2cccnc12

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 3/20 0.54
MAPK1 P28482 1/20 0.37
GRM4 Q14833 9/20 0.36
HSP90AA1 P07900 2/20 0.35
NPC1 O15118 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
CYP1A2 P05177 3/20 0.35
TDP1 Q9NUW8 2/20 0.35
POLB P06746 1/20 0.35
HTT P42858 2/20 0.34
KDM4E B2RXH2 1/20 0.34
GMNN O75496 1/20 0.34
LMNA P02545 1/20 0.34
TP53 P04637 1/20 0.34
MMP2 P08253 1/20 0.34
CYP3A4 P08684 1/20 0.34
CYP2D6 P10635 1/20 0.34
MAPT P10636 1/20 0.34
MMP9 P14780 1/20 0.34
ALOX15 P16050 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6923443 0.77 EPHX2 (0.69) EPHX2GRM4TDP1KDM4ELMNA
SCHEMBL2307327 0.75 HIF1A (0.46) EPHX2TDP1POLBTSHRHIF1A
SCHEMBL4069524 0.75 HSP90AA1 (0.43) EPHX2GRM4HSP90AA1NPC1L3MBTL1
SCHEMBL14804987 0.74 GRM4 (0.56) EPHX2MAPK1GRM4HTTKDM4E
SCHEMBL14804999 0.74 EPHX2 (0.60) EPHX2GRM4NPC1CYP1A2HTT
SCHEMBL1720865 0.73 EPHX2 (0.46) EPHX2MAPK1GRM4L3MBTL1CYP1A2
SCHEMBL6923970 0.72 GRM4 (0.60) EPHX2GRM4NPC1CYP1A2LMNA
SCHEMBL1720565 0.72 EPHX2 (0.45) EPHX2MAPK1GRM4CYP1A2HTT
SCHEMBL2235375 0.72 GRM4 (0.58) EPHX2GRM4NPC1POLBHTT
SCHEMBL14804995 0.71 EPHX2 (0.60) EPHX2GRM4NPC1CYP1A2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170145009-A1 HETEROCYCLIC COMPOUNDS THAT INHIBIT THE KINASE ACTIVITY OF MNK USEFUL FOR TREATING VARIOUS CANCERS EFFECTOR THERAPEUTICS, INC. 2017-05-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170145009-A1 HETEROCYCLIC COMPOUNDS THAT INHIBIT THE KINASE ACTIVITY OF MNK USEFUL FOR TREATING VARIOUS CANCERS MAP3K9, MAP3K19, MAP3K20 EPHX2 3362/4885MAPK1 166/4885GRM4 3422/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.